Novartis blueprints $36M vaccine research lab in NC

Novartis ($NVS) has blueprinted plans for a $36 million vaccine research lab in Holly Springs, NC, and plans to fill about 100 high-paying jobs to staff the addition.

The expansion follows the construction of Novartis' $600 million vaccine manufacturing plant, which opened last year. This new facility will include vaccine manufacturing capacity to produce experimental vaccines for research studies.

Novartis, which landed a 167-acre site in Holly Springs, is creating a vaccine research and manufacturing hub in the area alongside Merck ($MRK) and Pfizer ($PFE).

- here's the story from the News & Observer

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.